Why I’m not buying FTSE 100 giants AstraZeneca plc and Barclays plc for their dividends

Edward Sheldon looks at drugs giant AstraZeneca plc (LON: AZN) and banking behemoth Barclays plc (LON: BARC) and explains why he won’t be investing in these companies for their dividends.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today, I’m looking at two FTSE 100 shares that have been popular dividend stocks over the years. Right now, I’m not interested in buying either.

AstraZeneca

Healthcare giant AstraZeneca (LSE: AZN) made the headlines recently after it announced on the 27 July that results of its Mystic drug study showed a combination of two injectable immuno-therapies, Imfinzi (durvalumab) and tremelimumab, was no more effective than chemotherapy at treating stage IV lung cancer. The stock fell a significant 15% on the back of the news. The share price has now fallen around 22% since late June.  

While the decline in the share price has pushed AstraZeneca’s forward-looking yield up to a respectable 4.6%, there are several reasons I’m not interested in buying the company for its dividend at present.

Should you invest £1,000 in Mulberry Group Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Mulberry Group Plc made the list?

See the 6 stocks

The first is revenue growth. One of the key things that I look for when picking out dividend stocks is growth in the top line. That’s because, if revenue is rising, it’s considerably easier for a company to grow its profits and pay out an increasing dividend. In AstraZeneca’s case, revenue has been on the decline since FY2014, and City analysts expect a further drop in the top line of 6.5% this year.

Other things I look out for when assessing dividend stocks include a history of consistent dividend increases, and healthy dividend coverage of at least 1.5 times. However, AstraZeneca is forecast to cut its dividend by 23% this year, and even then, dividend coverage will still only be around 1.37 times.

So while I am bullish on the long-term prospects of the healthcare sector, I’m going to let AstraZeneca’s dividend slide for now, in the pursuit of more stable dividend opportunities in other areas of the market.

Barclays

Another stock I won’t be buying for its dividend is banking giant Barclays (LSE: BARC). While the company doesn’t look expensive on a forward-looking P/E ratio of just 11.6, its dividend prospects look rather underwhelming at present.

Barclays once offered a solid dividend yield, paying out 6.5p per share in FY2015. However, last year the bank slashed this by over half, and as a result the forward-looking yield is now just 1.4%.

As a rule, when investing in dividend stocks, I generally look for yields of around 3.5% or higher. It’s not rocket science to realise that the more cash investors receive in dividend payments, the more they have to reinvest and compound. If a company is growing its dividend at a phenomenal rate, I may be tempted to look at a yield closer to the 3% mark. However, anything lower than that doesn’t interest me. Barclays’ yield of 1.4% is therefore well below my threshold. 

Furthermore, future profitability at Barclays looks opaque, as the bank faces tight regulatory supervision and considerable competition from both established rivals and the challenger banks. With that in mind, I’d rather look at other sectors and companies for reliable dividend-paying stocks to add to my dividend growth portfolio. 

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Barclays. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

At $184, I reckon this S&P 500 juggernaut is still on sale

Our writer sees Amazon (NASDAQ:AMZN) as an attractive S&P 500 stock to consider while it is priced 23% lower than…

Read more »

Investing Articles

Cheap FTSE 250 shares to consider buying right now?

These FTSE 250 growth stocks had weak starts to 2025, and face short-term uncertainty. But their long-term valuations could be…

Read more »

Investing Articles

As stocks dive, is this a rare chance for ISA investors to build generational wealth?

Globally, stocks have pulled back significantly following the announcement of tariffs by the US president. Is this an opportunity for…

Read more »

Investing Articles

2 ultra-cheap shares to consider right now!

These cheap UK shares offer considerable growth and income potential over the long term, reckons our writer Royston Wild.

Read more »

Investing Articles

Legal & General Group shares go ex-dividend on 24 April – time to grab that 9% yield?

Harvey Jones holds Legal & General Group shares and is already looking forward to the next bumper dividend from this…

Read more »

Young female analyst working at her desk in the office
Investing Articles

3 FTSE 100 dividend stocks to consider buying while they’re on sale

Paul Summers reckons canny investors should think about snapping up quality, dividend-paying stocks while they're going cheap

Read more »

Investing Articles

2 cheap passive income shares to consider buying right now

The passive income we can earn from the UK stock market looks set to climb this year, and could even…

Read more »

Investing Articles

Down 15% in a month, this FTSE 100 dividend share offers investors a stunning 10.8% yield

Harvey Jones plucks out a FTSE 100 dividend share that offers frankly a quite staggering yield and is now a…

Read more »